Association between phosphate removal and markers of bone turnover in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 21, Issue 6, 2006, Pages 1626-1632

  Albalate, Marta ^a   de la Piedra, Concepción ^a   Fernández, Cristina ^a   Lefort, Mar ^a   Santana, Henar ^a   Hernando, Paloma ^a   Hernández, Jesús ^a   Caramelo, Carlos ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Bone turnover; Haemodialysis; Osteoprotegerin; Phosphate removal; PTH; RANKL

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; BICARBONATE; BIOLOGICAL MARKER; CALCIUM; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; BLOOD SAMPLING; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSATE LEVEL; FEMALE; HEMODIALYSIS; HUMAN; MALE; MULTIPLE REGRESSION; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DEMINERALIZATION, PATHOLOGIC; CASE-CONTROL STUDIES; DIALYSIS SOLUTIONS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATES; RANK LIGAND; RENAL DIALYSIS; VITAMIN D;

EID: 33746006507     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl034     Document Type: Article

References (19)

1. Block GA, Hulbert-Shearon MS, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic haemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 607-617
2. Stevens LA, Djurdjev O, Cardew S, Cameron E, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779
3. Drüeke T. Renal osteodystrophy: Management of hyperphosphataemia. Nephrol Dial Transplant 2000; 15 [Suppl 5]: 32-33
4. DeSoi C, Umans J. Phosphate kinetics during high-flux haemodialysis. J Am Soc Nephrol 1993; 4: 1214-1218
5. Minutolo R, Bellizzi V, Cioffi M et al. Postdialytic rebound of serum phosphorus: Pathogenetic and clinical insights. J Am Soc Nephrol 2002; 13: 1046-1054
6. Albalate M, Fernández C, López MD et al. Se puede aumentar la eliminación de fósforo con la hemodiálisis convencional? Nefrología 2003; 23: 520-527
7. Ureña P, de Vernejoul M. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156
8. Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460-1468
9. Reichel H, Esser A, Roth H, Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003; 18: 759-766
10. Boyle W, Simonet W, Lacey D. Osteoclast differentiation and activation. Nature 2003; 423: 337-342
11. Kazama JJ, Kato H, Sato T et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 2002; 17: 1860-1861
12. Avbersek-Luznik I, Malesic I, Rus I, Marc J. Increased levels of osteoprotegerin in haemodialysis patients. Clin Chem Lab Med 2002; 40: 1019-1023
13. Haas M, Leko-Mohr Z, Roschger P et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in haemodialysis patients. Am J Kidney Dis 2002; 39: 580-586
14. Coen G, Ballanti P, Balducci A et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002; 17: 233-238
15. Kazama JJ, Shigematsu T, Yano K et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002; 39: 525-532
16. Moiri D, Masaki I, Fujino K, Tsuchiya M. Efficacy of a continuous syringe extraction method for monitoring haemodialysis ultrafiltrate. ASAIO J 2000; 46: 461-463
17. Malyszko J, Malyszko JS, Wolczynski S, Mysliwiec M. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. Transplant Proc 2003; 35: 2227-2229
18. Frick KK, Bushinsky DA. Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclooxygenase-dependent mechanism. J Bone Miner Res 2003; 18: 1317-1325
19. Bevington A, Brough D, Baker FE, Hattrsley J, Walls J. Metabolic acidosis is a potent stimulus for cellular inorganic phosphate generation in uraemia. Clin Sci 1995; 88: 405-412